PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
Executive Summary
United Therapeutics' recently approved pulmonary arterial hypertension drug Adcirca threatens to close in on the vast lead held by Actelion's Tracleer, though surpassing the market pioneer seems nearly impossible. Not to mention, the Swiss-based biotech has an ace up its sleeve with the expansive REVEAL patient registry
You may also be interested in...
U.S./EU Filings Position Bayer Compound As First Approval For CTEPH
Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.
U.S./EU Filings Position Bayer Compound As First Approval For CTEPH
Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.
Gleevec For What? Imatinib NDA For PAH Will Face Safety Questions At Advisory Panel
Novartis said there was a higher rate of unspecified serious adverse events in the active arm of the pivotal trial for pulmonary arterial hypertension.